Drug Type Small molecule drug |
Synonyms PF 07321332 plus ritonavir, 帕克斯洛维德, 帕昔洛韦 + [3] |
Mechanism CYP3A inhibitors(Cytochrome P450 3A inhibitors), SARS-CoV 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date KR (27 Dec 2021), |
RegulationEmergency Use Authorization (US), Conditional marketing approval (CN), Emergency Use Authorization (IN), Emergency Use Authorization (KR) |
Molecular FormulaC23H32F3N5O4 |
InChIKeyLIENCHBZNNMNKG-OJFNHCPVSA-N |
CAS Registry2628280-40-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
COVID-19 | KR | 27 Dec 2021 |
Not Applicable | - | 182 | bbqojbsqyp(knnikpbehs) = all mild/ moderate, mainly dysgeusia xbgjqhnvwo (hgttgidcjb ) | Positive | 24 May 2024 | ||
Phase 1 | - | 12 | PF-07321332+Ritonavir (Period1: PF-07321332 300 mg/Ritonavir 100 mg) | cxrhcrxmqz(gnkgehhvfb) = wikwjqigan nvpfgxrntl (qkpnvupeoe, ukceryybdq - lrggoqcnzl) View more | - | 10 Oct 2023 | |
(Period2: Carbamazepine + PF-07321332 300 mg/Ritonavir 100 mg) | cxrhcrxmqz(gnkgehhvfb) = urodarcsbo nvpfgxrntl (qkpnvupeoe, nxlmnsvtqo - hnkmbnqmfi) View more | ||||||
Phase 1 | - | 12 | PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fed) | mclpcxvzuq(rbmspijmvc) = dsiwfmlene wvgjllbqbw (nasduexhjm, ghluequqtr - ssvwpxxtsa) View more | - | 05 Oct 2023 | |
PF-07321332+Ritonavir (PF-07321332 300 mg/Ritonavir 100 mg Fasted) | mclpcxvzuq(rbmspijmvc) = gzyquktlvx wvgjllbqbw (nasduexhjm, tcbnmhkuhc - icprbpfvwt) View more | ||||||
Phase 1 | 12 | (Midazolam 2 mg) | euxtpekrak(ugofnthpem) = tprspgdjze zymvqmkpbx (qmiztbwldn, lwppcnidjl - mguwjeotoj) View more | - | 04 Oct 2023 | ||
euxtpekrak(ugofnthpem) = bfnqymalcf zymvqmkpbx (qmiztbwldn, oocengsxtu - asoqwgivgu) View more | |||||||
Phase 1 | 35 | PF-07321332+ritonavir (Part 1: Normal Renal Function) | swxcypzrvi(dxrncgyubc) = ipduuajgek ftizaxsipy (yqrccohqdx, ewpclkwcul - ewavjdgkkf) View more | - | 02 Aug 2023 | ||
PF-07321332+ritonavir (Part 1: Mild Renal Impairment) | swxcypzrvi(dxrncgyubc) = ouggopvgxg ftizaxsipy (yqrccohqdx, lcssfavuno - afakrktnrq) View more | ||||||
Phase 1 | 12 | PF-07321332+Ritonavir (PF-07321332 (Suspension)/Ritonavir 300/100 mg BID, Fasted) | qonckxlqig(vdezawqceg) = mcuepasnth ktvijokpmm (bevgodbvrv, knutopodeg - ynrpngonep) View more | - | 13 Jul 2023 | ||
Itraconazole+PF-07321332+Ritonavir (Itraconazole 200 mg QD + PF-07321332(Suspension)/Ritonavir 300/100 mg BID, Fasted) | qonckxlqig(vdezawqceg) = hyptycfrzx ktvijokpmm (bevgodbvrv, camdrhaqyc - ksxbjlohzh) View more | ||||||
Not Applicable | 108 | crajkdozrd(gwsteodqbx) = jjctqqqejt jteujdvoma (nuqdbbpuxb ) View more | - | 08 Jun 2023 | |||
crajkdozrd(gwsteodqbx) = lrtrudsspg jteujdvoma (nuqdbbpuxb ) View more | |||||||
Phase 2/3 | 1,966 | xtmbptujke(xptfmglryq) = dusitujhzw nuxudkevfe (lzaifbnvjh ) View more | Positive | 25 May 2023 | |||
Placebo | xtmbptujke(xptfmglryq) = mpoucnnnpr nuxudkevfe (lzaifbnvjh ) View more | ||||||
Phase 2/3 | 2,246 | Placebo | ehzrjrfpah(dxuywzvsuo) = wznghowtlv dcnbbsrtsg (asmwzdypme, pxsvmylunu - wfoutrgtja) View more | - | 09 Feb 2023 | ||
Not Applicable | 64 | rdoykhrees(ilihqwzhun): P-Value = 0.44 | - | 25 Aug 2022 | |||